However, the in vivo antitumor efficacy of IL-21R-TCR-T was only validated in a relatively artificial HCC subcutaneous model in our study since no TCR-T therapy against orthotopic HCC model was reported until now. The gene discussed is IL21R; the disease is hepatocellular carcinoma.